%PDF-1.4
%
66 0 obj
<>
endobj
63 0 obj
<>
endobj
124 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-03T15:12:16Z
2024-03-28T04:26:41-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T04:26:41-07:00
application/pdf
Heather
2001-373april02
uuid:f4b814f7-1dd1-11b2-0a00-aa0927bd3700
uuid:f4b814f9-1dd1-11b2-0a00-5b0000000000
endstream
endobj
52 0 obj
<>
endobj
53 0 obj
<>
endobj
67 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
12 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
15 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
18 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
31 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
34 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
37 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
158 0 obj
[162 0 R]
endobj
159 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
0.02499 Tw 8 0 0 8 61 714.5293 Tm
[(5.)-875 (Layzer RB. Inflammatory and immune disorders. In: Layzer RB,)]TJ
-0.00011 Tc 1.675 -1.25 Td
[(editor)54.8 (. Neuromuscular manifestations of systemic disease.)]TJ
0 Tc 0 -1.25 TD
(Philadelphia: Davis; 1985:227-8.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(6.)-875.1 (Kraus )54.8 (A, Cifuentes M, )17.7 (V)60 (illa )54.8 (AR, Jakez J, Reyes E, )54.8 (Alarcon-Segovia)]TJ
1.675 -1.25 Td
[(D. Myositis in primary Sj\366gren\222)54.8 (s syndrome. Report of 3 cases. )]TJ
0 Tc T*
(J Rheumatol 1994;21:649-53.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(7.)-875.1 (Leroy JP)110.7 (, Drosos )54.8 (AA, )36.8 (Y)55.1 (iannopoulos P)110.7 (, Moutsopoulos HM.)]TJ
0 Tc 1.675 -1.25 Td
(Intravenous pulse cyclophosphamide therapy in myositis and)Tj
T*
[(Sj\366gren\222)54.9 (s syndrome. )54.8 (Arthritis Rheum 1990;33:1579-81.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(8.)-875.1 (Olsen NJ, Park JH. Skeletal muscle abnormalities in patients with)]TJ
0 Tc 1.675 -1.25 Td
[(fibromyalgia. )54.9 (Am J Med Sci 1998;315:351-8.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(9.)-875.1 (Lindman R, Hagber)17.7 (g M, Bengtsson )54.8 (A, Henriksson KG, )17.7 (Thornell)]TJ
0 Tc 1.675 -1.25 Td
(LE. Capillary structure and mitochondrial volume density in the)Tj
T*
(trapezius muscle of chronic trapezius myalgia, fibromyalgia and)Tj
T*
(healthy subjects. J Musculoskel Pain 1995;3:5-22.)Tj
-2.175 -1.25 Td
[(10.)-875 (Engel )54.8 (AG, Hohlfeld R, Banker BQ. )17.7 (The polymyositis and)]TJ
2.175 -1.25 Td
[(dermatomyositis syndrome. In: Engel )54.8 (AG, Franzini-Armstrong C,)]TJ
-0.00011 Tc T*
[(editors. Myology)64.8 (. New )36.8 (Y)100 (ork: McGraw-Hill; 1994:1335-83.)]TJ
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Alexander EL. Neuromuscular complications of primary Sj\366gren\222)54.8 (s)]TJ
2.1381 -1.25 Td
[(syndrome. In: )17.7 (T)69.7 (alal N, Moutsopoulos HM, Kassan SS, editors.)]TJ
0 Tc T*
[(Sj\366gren\222)54.9 (s syndrome. Clinical and immunological aspects. Berlin:)]TJ
0.0072 Tw T*
[(Springer V)111.1 (erlag; )-17.8 (1987:61-82.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(12.)-875.1 (Garlepp MJ, Mastaglia FL. Inclusion body myositis. J Neurol)]TJ
0 Tc 2.175 -1.25 Td
[(Neurosur)17.8 (g Psychiatry 1996;60:251-5.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(13.)-875.1 (Chad D, Good P)110.7 (,)-0.1 ( )54.8 (Adelman L, Bradley )17.7 (WG, Mills J. Inclusion body)]TJ
2.175 -1.25 Td
[(myositis associated with Sj\366gren\222)54.8 (s syndrome. )54.8 (Arch Neurol)]TJ
0 Tc 0 Tw T*
(1982;39:186-8.)Tj
0.02499 Tw -2.175 -1.25 Td
[(14.)-875 (Gutmann L, Govindan S, Riggs JE, Schochet SS. Inclusion body)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(myositis and Sj\366gren\222)54.8 (s syndrome. )54.8 (Arch Neurol 1985;42:1021-2.)]TJ
0 Tc -2.175 -1.25 Td
[(15.)-875 (Khraishi MM, Jay )17.7 (V)129.1 (, Keystone EC. Inclusion body myositis in)]TJ
2.175 -1.25 Td
[(association with vitamin B12 deficiency and Sj\366gren\222)54.9 (s syndrome. )]TJ
T*
(J Rheumatol 1992;19:306-9.)Tj
-2.175 -1.25 Td
[(16.)-875 (Dalakas MC. Immunopathogenesis of inflammatory myopathies.)]TJ
-0.00011 Tc 2.175 -1.25 Td
(Ann Neurol 1995;37 Suppl:S74-S86.)Tj
-2.175 -1.25 Td
[(17.)-875.1 (Emslie-Smith )54.8 (AM, Engel )54.8 (AG. Microvascular changes in early and)]TJ
0 Tc 2.175 -1.25 Td
[(advanced dermatomyositis: )54.8 (A)-219.8 (quantitative study)65 (. )54.8 (Ann Neurol)]TJ
0 Tw T*
(1990;27:343-56.)Tj
0.0249 Tw -2.175 -1.25 Td
[(18.)-875 (Kissel JT)74 (, Halterman RK, Rammohan KW)91.8 (, Mendell JR. )17.7 (The)]TJ
2.175 -1.25 Td
(relationship of complement-mediated microvasculopathy to the)Tj
T*
(histologic features and clinical duration of disease in)Tj
T*
[(dermatomyositis. )54.9 (Arch Neurol 1991;48:26-30.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(19.)-875.1 (Molina R, Provost )17.7 (TT)73.9 (, )54.8 (Arnett FC, et al. Primary Sj\366gren\222)54.8 (s)]TJ
0 Tc 2.175 -1.25 Td
(syndrome in men. Clinical, serologic, and immunogenetic features.)Tj
T*
(Am J Med 1986;80:23-31.)Tj
-2.175 -1.25 Td
[(20.)-875 (Ringel SP)110.8 (, Forstot JZ, )17.7 (T)69.8 (an EM, )17.7 (W)79.8 (ehling C, Griggs RC, Butcher D.)]TJ
2.175 -1.25 Td
[(Sj\366gren\222)54.9 (s syndrome and polymyositis or dermatomyositis. )54.9 (Arch)]TJ
T*
(Neurol 1982;39:157-63.)Tj
-2.175 -1.25 Td
[(21.)-875 (V)60.1 (itali C, Bombardieri S, Moutsopoulos HM, et al. Preliminary)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(criteria for the classification of Sj\366gren\222)54.8 (s syndrome. Results of a)]TJ
0 Tc T*
(prospective concerted action supported by the European)Tj
T*
[(Community)64.9 (. )54.9 (Arthritis Rheum 1993;36:340-7.)]TJ
-2.175 -1.25 Td
[(22.)-875 (V)60.1 (itali C, Bombardieri S, and the European Study Group on)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(Diagnostic Criteria for SS. )17.7 (The European classification criteria for)]TJ
T*
[(Sj\366gren\222)54.8 (s syndrome. Proposal for a modification of the rules for)]TJ
0 Tc T*
(classification suggested by the analysis of the receiver operating)Tj
-0.00011 Tc T*
(characteristic curve of the criteria performance [abstract]. J)Tj
0 Tc T*
(Rheumatol 1997;24 Suppl 50:38.)Tj
-2.175 -1.25 Td
[(23.)-875 (W)79.8 (olfe F)79.8 (,)0.1 ( Smythe HA, )36.8 (Y)111.1 (unus MB, et al. )17.7 (The )54.8 (American College of)]TJ
2.175 -1.25 Td
(Rheumatology 1990 criteria for the classification of fibromyalgia:)Tj
33 72.5 Td
[(report of the Multicenter Criteria Committee. )54.8 (Arthritis Rheum)]TJ
0 Tw T*
(1990;33:160-72.)Tj
0.02499 Tw -2.175 -1.25 Td
[(24.)-875 (Burckhardt CS, Clark SR, Bennett RM. )17.8 (The Fibromyalgia Impact)]TJ
2.175 -1.25 Td
(Questionnaire: development and validation. J Rheumatol)Tj
0 Tw T*
(1991;18:728-33.)Tj
-0.00011 Tc 0.0249 Tw -2.175 -1.25 Td
[(25.)-875.1 (Fries JF)79.7 (, Spitz P)110.7 (, Kraines RG, Holman HR. Measurement of patient)]TJ
0 Tc 2.175 -1.25 Td
[(outcome in arthritis. )54.9 (Arthritis Rheum 1980;23:137-45.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(26.)-875.1 (Nordenski\366ld UM, Grimby G. Grip force in patients with)]TJ
0 Tc 2.175 -1.25 Td
[(rheumatoid arthritits and fibromyalgia and in healthy subjects. )54.9 (A)]TJ
T*
(study with the Grippit instrument. Scand J Rheumatol )Tj
0 Tw T*
(1993;22:14-9.)Tj
0.02499 Tw -2.175 -1.25 Td
[(27.)-875 (Lorig K, Chastain RL, Ung E, Shoor S, Holman HR. Development)]TJ
2.175 -1.25 Td
[(and evaluation of a scale to measure perceived self-ef)17.8 (ficacy in)]TJ
T*
[(people with arthritis. )54.9 (Arthritis Rheum 1989;32:37-44.)]TJ
-2.175 -1.25 Td
[(28.)-875 (Burckhardt CS, )54.8 (Archenholtz B, Bjelle )54.8 (A. Measuring the quality of)]TJ
-0.00011 Tc 2.175 -1.25 Td
(life of women with rheumatoid arthritis or systemic lupus)Tj
T*
[(erythematosus. )54.8 (A)-219.9 (Swedish version of the Quality of Life Scale)]TJ
0 Tc T*
(\(QOLS\). Scand J Rheumatol 1992;21:190-5.)Tj
-2.175 -1.25 Td
[(29.)-875 (Mannerkorpi K, Ekdahl C. )54.8 (Assessment of functional limitation and)]TJ
2.175 -1.25 Td
(disability in patients with fibromyalgia. Scand J Rheumatol)Tj
0 Tw T*
(1997;26:4-13.)Tj
0.0249 Tw -2.175 -1.25 Td
[(30.)-875 (Medical Research Council of the United Kingdom. )54.8 (Aids to the)]TJ
2.175 -1.25 Td
(examination of the peripheral nervous system. London: Pendragon)Tj
T*
(House; 1978.)Tj
-2.175 -1.25 Td
[(31.)-875 (Henriksson KG. \223Semi-open\224 muscle biopsy technique. )54.8 (A)-219.8 (simple)]TJ
2.175 -1.25 Td
[(out-patient procedure. )54.9 (Acta Neurol Scand 1979;59:317-23.)]TJ
-2.175 -1.25 Td
[(32.)-875 (Boenisch )17.8 (T)74 (. Staining methods. In: )54.9 (Anon. Handbook,)]TJ
2.175 -1.25 Td
(immunochemical staining methods. 2nd ed. Carpinteria, CA: Dako)Tj
T*
(Corp.; 1989.)Tj
-2.175 -1.25 Td
[(33.)-875 (Str\366mbeck B, Ekdahl C, Manthorpe R, )17.7 (W)39.8 (ikstr\366m I, Jacobsson L.)]TJ
2.175 -1.25 Td
[(Health-related quality of life in primary Sj\366gren\222)54.9 (s syndrome,)]TJ
T*
(rheumatoid arthritis and fibromyalgia compared to normal)Tj
T*
(population data using SF 36. Scand J Rheumatol 2000;29:20-8.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(34.)-875.1 (W)79.7 (olfe F)79.7 (, Ross K, )54.8 (Andersson J, Russell IJ, Hebert L. )17.7 (The prevalence)]TJ
0 Tc 2.175 -1.25 Td
(and characteristics of fibromyalgia in the general population.)Tj
T*
(Arthritis Rheum 1995;38:19-28.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(35.)-875.1 (Y)111 (unus MB, Masi )54.8 (A)111 (T)73.9 (, Miller KS, Feigenbaum SL. Primary)]TJ
0 Tc 2.175 -1.25 Td
(fibromyalgia \(fibrositis\): clinical study of 50 patients with matched)Tj
T*
[(normal controls. Semin )54.9 (Arthritis Rheum 1981;1)36.9 (1:151-71.)]TJ
-2.175 -1.25 Td
[(36.)-875 (Bengtsson )54.9 (A, B\344ckman E, Lindblom B, Skogh )17.8 (T)74 (. Long term)]TJ
2.175 -1.25 Td
(follow-up of fibromyalgia patients: clinical symptoms, muscular)Tj
T*
[(function, laboratory tests \227 an eight year comparison study)64.9 (. )]TJ
T*
(J Musculoskel Pain 1994;2:67-80.)Tj
-2.175 -1.25 Td
[(37.)-875 (Henriksson KG. Is fibromyalgia a distinct clinical entity? Pain)]TJ
2.175 -1.25 Td
[(mechanisms in fibromyalgia syndrome. )54.8 (A)-219.8 (myologist\222)54.9 (s view)64.9 (.)]TJ
T*
[(Balliere\222)54.9 (s Clin Rheumatol 1999;13:455-61.)]TJ
-2.175 -1.25 Td
[(38.)-875 (Askanas )17.7 (V)129.1 (, King Engel )17.7 (W)91.8 (. Newest approaches to diagnosis and)]TJ
2.175 -1.25 Td
(pathogenesis of sporadic inclusion-body myositis and hereditary)Tj
T*
[(inclusion-body myopathies, including molecular)19.8 (-pathologic)]TJ
-0.00011 Tc T*
[(similarities to )54.8 (Alzheimer disease. In: )54.8 (Askanas )17.7 (V)129.1 (, Serratrice G, King)]TJ
0 Tc T*
[(Engel )17.8 (W)91.8 (, editors. Inclusion body myositis and myopathies.)]TJ
T*
(Cambridge: Cambridge University Press; 1998:3-78.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(39.)-875.1 (Coquet M, Coquet O, Ferrer X, Julien J, )17.7 (V)60 (ital C. Uncommon)]TJ
0 Tc 2.175 -1.25 Td
(clinicopathological forms of sporadic inclusion body myositis:)Tj
-0.00011 Tc T*
[(report of 4 cases. In: )54.8 (Askanas )17.7 (V)129.1 (, Serratrice G, King Engel )17.7 (W)91.7 (,)]TJ
0 Tc T*
(editors. Inclusion body myositis and myopathies. Cambridge:)Tj
-0.00011 Tc T*
(Cambridge University Press; 1998:126-36.)Tj
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/TT1 1 Tf
0 Tc 8 0 0 8 54.5 35.9844 Tm
(Lindvall, et al: Subclinical myositis)Tj
0 Tw 61.4375 -0.0313 Td
(725)Tj
ET
0 0 0 0 scn
/GS0 gs
102.25 58.75 407.5 -10.83 re
f*
0.5 w
102.25 58.75 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
105 0 obj
<>
endobj
129 0 obj
<>
endobj
74 0 obj
<>
endobj
69 0 obj
<>
endobj
71 0 obj
<>
endobj
99 0 obj
<>stream
HV lޛ]Y>06vCl/!xmR.s .>@!C 7@@!&BJJhbpSJ&)B("I;fm $Ry{] Pc'lO B)S\(]ŕӻ%P
(YHs+~U
Q]CW,}(;w/Xرk759A\| V+.͕o?D{`yέ7. 3Oߊ9XLWZ9mr 95ҭd+'RmKIqo b)ׯ]lB"%\_EalG!]ʱ]`0#U
aV#rכ#N1/'ZD18T+bEG+@<\
i=oͣW[C1~^LdqNL+g}aDX $ouYa[JhHC'HƝXϸu,q\U'@)eGuiHeee6D{
#ȝO!#EgKm2M>'yH~*u=DNV7(B5h~m$ؙh=<pE0wV\2Qrd)C9I括|o"k):iD\+e=syvos}pMbhm<$8Hê
aW8Q)*\bTe%_NKj<)O˯5yS*i5>櫓]Z6][Ui}ގ4XN+ʴ*V].ZFv$]1i8;_wvnr`+M -H6H.+\]|u2IQ(ȻNj#FJV6uĻ{>ґgYg*07
Ɗ1?+x~K orz2lFzgWnSǴ)퓓ڵ}u|-bcMU@fFT3#<6o)D0u1@LK˲Yz,-KAlgfC\5t1]Q/9"̼Pe5hF}5-&9>3ܨNIK̂q~_nȓm0uV{4n:3 k\Ȋ+1JS,he&f+OG+fT2=/Xcihb6\Kn1")V2nõ7%QjlI`nÌPxV5O Ƚ'%[oGͧ'
|(ZޫZɮO^6͒{z@w˛yU6fa:
*pq?),f@52`ƛOKGKُfVɞ?l
z{+FK7;T(`ErXwnٚ:/f1x3:7'Ȕ[&T=^Gmkf;e3C81
l+n)i$:IJ jS8w"uQagk)]G~Ir]v1{ԏ&_HLua1%ͺ.Ȟ=u"R>bm((&L Ԅ/J _PSsBjG*
样/qwWWkeIjAUX)2o':E=0dÚmc {P
~Y#f6^+X-|߁}L؊AcH. bx;{xi8G@}TC[vaq>Y=)gԮkD/>z^?8с\b:}g GxA.C^-˝DzA} yۛUɽ3F֢ U O@a3Xf9r?GT(Pn4< P)"_4
>2@|Ȁk L]a崯f/ZGm*dE%{*yttdRU@J^0W *
dN% ZT@ L V6 v9cZrT$\%\۸6q-"m"o.$\*Eo#xDD8A grm
h4 6H
Ҭ)+\$<ε,߅C@HZJCRnHR--~-uK9Rf7<^gW>gs2r,)$:KkO`IaTsO&'G_˨GU ?,D+aPwii7"wLrG.<0JAڕƀkP-UKk$tcNF:J'|*^OnmR_yTrBNw=-Gz^yƔ(v'Y!Ri%ħ٘B*wu{5Ow-BR<9w'>"7_zhXc"Kp
#(c$83/y~xf,Vg3R͠tݙeom?АqD
9i4f0mi.m?qpqJp JR8/I)Pj=2'g<67%̅ s!7?6{溄ߚa_\#Y`Ebnrb5";X3.G[4 A |eF:1=B!67"~d3&+4 UP%9fbQjX٣],hlRX)V1xHEi46ź0:>+)ƭX'd1[0ٳb02gÏkn>x-;حxz1aR9b5X5#H5^VYil 'F)xH;RlּVlEԖF1\!4+W}=3 Bc(6f
j]6dg&p؋nܜ;9jb*2MN:KY.{ Ҽ"\Ҳϟj